The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2022 Euromoney, a part of the Euromoney Institutional Investor PLC.

Vaccine finance: Why the Covax Facility deserves a closer look

As the world cheered news of a potential Covid-19 vaccine in early November, important steps were being taken on equitable manufacture and distribution as well.


In early November, vaccine alliance Gavi – a public-private global health partnership to increase access to immunization in lower-income countries – announced the appointment of Citi as financial adviser to its Covax Facility.

The Facility aims to procure, equitably allocate and deliver two billion doses of safe and effective Covid-19 vaccines by the end of 2021.

Covax was launched in April in response to the coronavirus pandemic. It is a global collaboration of pharmaceutical companies, governments, multilaterals and non-governmental organizations.

This may be one of the most important risk structures and finance mechanisms of our era – everyone should be paying attention to it.

Some 94 higher-income economies have joined the programme as self-financing members. They pay into the Covax Facility, which provides a large portfolio of vaccine manufacturers with investments and incentives to ensure they are ready to produce the doses needed as soon as a vaccine is approved.

The Covax Facility could serve as a blueprint for the management of future global crises

Most of the vaccines in the portfolio won’t work, but the Facility is a crucial mechanism for fairness. Collaboration and pooled purchasing power should mean lower prices from manufacturers, to everyone's benefit.


You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree